Advertisement

Related Videos

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Opportunities to Optimize Cancer Policies Panel Discussion

Advertisement

Advertisement




Jul
17
Today In Oncology
Meta-Analysis Highlights Cardiovascular Safety Advantage of Second-Generation BTK Inhibitors
ctDNA Status May Predict Benefit From Adjuvant Chemotherapy After Resection of Colorectal Liver Metastases
Tumor Microenvironment Ecotypes May Explain Differences in Multiple Myeloma Outcomes
Expert Dermatologists Outperform AI Foundation Models in Real-World Skin Cancer Diagnosis
Node-Negative Breast Cancer 20-Year Outcomes With IM-MS Lymph Node Irradiation
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo